ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Pulmonary Disease

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,169Medicare Part D Prescriptions Filled, Including Refills

Rank: 13 out of 568

$567K Total Retail Price of All Prescriptions

Rank: 43 out of 568

490 Patients Receiving at Least One Drug in Part D
88%Patients 65 Years and Older
78% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New York
Lower avg

Schedule Two
Controlled Substances

14% of this provider’s 490 patients filled at least one prescription for a schedule two drug, compared to an average of 1%.

Schedule Three
Controlled Substances

5% of this provider’s 490 patients filled at least one prescription for a schedule three drug, compared to an average of 1%.

Risky Drugs to Seniors

2% of this provider’s 8,322 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 0%.

Brand Name Drugs

28% of this provider’s prescriptions were for brand-name drugs, compared to an average of 56%.

Prescription Price

$62 was the average price of a prescription from this provider, compared to $126 among peers.

Prescriptions per Patient

19 is the average number of prescriptions (including refills) per patient, compared to an average of 11.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New York
FUROSEMIDE 375 361 1 11
SIMVASTATIN 355 342 2 3
METOPROLOL TARTRATE 327 314 3 14
LEVOTHYROXINE SODIUM 307 276 4 10
WARFARIN SODIUM 303 300 5 22
AMLODIPINE BESYLATE 294 277 6 6
OMEPRAZOLE 205 179 7 8
ADVAIR DISKUS 202 156 8 2
LISINOPRIL 200 187 9 12
RANITIDINE HCL 184 184 10 41
FLUTICASONE PROPIONATE 184 125 10 21
METFORMIN HCL 168 154 12 13
ATENOLOL 134 127 13 25
GABAPENTIN 124 107 14 36
SPIRIVA 124 97 14 1
POTASSIUM CHLORIDE 120 115 16 52
MIRTAZAPINE 114 114 17 56
CARVEDILOL 112 104 18 37
DONEPEZIL HCL 109 109 19 34
JANUVIA 107 101 20 32
TAMSULOSIN HCL 103 103 21 35
HYDROCHLOROTHIAZIDE 101 97 22 19
QUETIAPINE FUMARATE 101 94 22 93
CITALOPRAM HBR 101 101 22 51
LACTULOSE 91 91 25 92
DIOVAN 89 83 26 29
SINGULAIR 86 73 27 9
DIVALPROEX SODIUM 81 81 28 127
LOSARTAN POTASSIUM 78 72 29 23
PREDNISONE 73 59 30 4
CLOPIDOGREL 71 69 31 38
FAMOTIDINE 70 56 32 65
METOCLOPRAMIDE HCL 70 64 32 158
SYMBICORT 68 52 34 7
VALPROIC ACID 67 67 35 130
RISPERIDONE 67 67 35 96
DIGOXIN 67 57 35 85
CARBIDOPA-LEVODOPA 65 65 38 101
OXYCODONE-ACETAMINOPHEN 61 55 S2 39 70
SEROQUEL 60 55 40 162
PLAVIX 56 55 41 44
HYDRALAZINE HCL 54 47 42 101
SERTRALINE HCL 53 50 43 61
METOLAZONE 51 45 44 175
MONTELUKAST SODIUM 51 46 44 24
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Dec. 30, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.